ギラン・バレー症候群およびフィッシャー症候群の治療(<特集>免疫性神経疾患とアフェレシス,新しい展望)

概要

論文の詳細を見る
Guillain-Barre syndrome (GBS) is an acute inflammatory neuropathy thought to be due to autoimmune disease. Among specific therapeutic interventions aimed at mitigating the harmful effects of autoantibodies, plasma exchange and intravenous immunoglobulin (IVIg) have been shown to be equally efficacious. In contrast. corticosteroids alone do not alter the outcome of GBS. In a recent control study, it was assessed whether methylprednisolone, when taken with IVIg, improves outcome when compared with IVIg alone. In conclusion, there was no significant difference between the two resgimens. Fisher's syndrome is characterized by the clinical triad : ophthalmoplegia, ataxia, and areflexia. Although several reports have described possible beneficial effects of plasmapheresis or IVIg in treating Fihser's syndrome, the results are not sufficient to reach a conclusion. Our previous case control study showed plasmapheresis had no beneficial effect, but IVIg appeared to shorten the time required to resolve ophthalmoplegia. IVIg may be an option in treatment for Fisher's syndrome.
日本アフェレシス学会の論文
2004-10-31